Balanced news tone
News Sentiment
VRTX sentiment intelligence
Vertex Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+0.1% over one week, +7.5% over four weeks, trend active, and near fair-value range.
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 07:00
- Source
- Market source
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Market source
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Market source
Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- The Motley Fool
Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Market source
Is Vertex Pharmaceuticals (VRTX) Offering Opportunity After Recent Pipeline Headlines And DCF Valuation Gap
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 07:00
- Source
- simplywall.st
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Vertex Pharmaceuticals Stock Analysis: 1991 IPO Growth and 2026 Outlook - News and Statistics
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 07 May 2026 07:00
- Source
- IndexBox
Vertex Pharmaceuticals (VRTX) Profitability Return Tests Bullish Narratives Ahead Of Q1 2026 Earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- simplywall.st
Vertex Reports First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 May 2026 07:00
- Source
- Business Wire
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 04 May 2026 07:00
- Source
- The Globe and Mail
Why Vertex Pharmaceuticals Stock Looks Undervalued in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- TIKR.com
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Market source
Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX)
- Tone
- Positive 80/100
- Event
- Macro sensitivity
- Published
- 02 Apr 2026 07:00
- Source
- Seeking Alpha
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- CNBC
Vertex Pharmaceuticals Stock Pops 5% On Successful Late Stage Kidney Disease Drug Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- TIKR.com